---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-093997"
form_type: "8-K"
ticker: "BBOT"
cik: "0001869105"
company_name: "BridgeBio Oncology Therapeutics, Inc."
filed_at: "2026-03-05T23:59:59+00:00"
generated_at: "2026-05-15T19:54:29.203728+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# BBOT reports Q4 net loss $38.8M; cash runway into 2028; pipeline advances

## Summary
- Q4 2025 net loss $38.8M (vs $19.7M in Q4 2024); full year net loss $134M (vs $74.3M).
- Cash and equivalents $425.5M; expected to fund operations into 2028.
- R&D expenses Q4 $38.1M (vs $19.5M); G&A $5.3M (vs $2.3M); increases driven by clinical and manufacturing.
- BBO-8520 monotherapy 65% ORR in KRAS G12C NSCLC; BBO-11818 first confirmed PR in PDAC; BBO-10203 no hyperglycemia.
- Clinical data readouts across all three programs expected in H2 2026; internal combinations opening later in 2026.

## SEC filing metadata
- accession: 0001193125-26-093997
- form_type: 8-K
- ticker: BBOT
- cik: 0001869105
- company_name: BridgeBio Oncology Therapeutics, Inc.
- filed_at: 2026-03-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1869105/000119312526093997/0001193125-26-093997-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1869105/000119312526093997/bbot-20260305.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-093997
- JSON: https://secwatch.observer/filing/0001193125-26-093997.json
- Plain text: https://secwatch.observer/filing/0001193125-26-093997.txt

## Key facts
- Earnings Releases
  BridgeBio Oncology Therapeutics, Inc. reported financial results for the fourth quarter and full year ended December 31, 2025.
  - Period: the fourth quarter and full year ended December 31, 2025
  - Result: reported results
  source text: BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (Nasdaq: BBOT), a clinical-stage biopharmaceutical company focused on RAS-pathway malignancies, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided a business update
  evidence_url: https://www.sec.gov/Archives/edgar/data/1869105/000119312526093997/0001193125-26-093997-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.